Rapid-acting prandial insulin analog.
Reference facts
- Also known as
- NovoLog, Fiasp
- Category
- Hormonal & Pituitary
- Mechanism of action
- Rapid-acting prandial insulin analog.
- Targets
- Insulin receptor
- Indications under research or approved
- Diabetes — prandial insulin
- Regulatory status (reference entry)
- FDA-approved (2000)
- Half-life
- ~1 hour
- Sequence
- GIVEQCCTSICSLYQLENYCN
- Sequence notes
- Rapid-acting insulin: B-chain Pro28 → Asp, reducing dimerization.
- Molecular weight (Da)
- 5826
- PDB accession
- 1ZEH
- Originator / sponsor
- Novo Nordisk
- First reported
- 1994
Primary References
Explore research articles about Insulin Aspart
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.